A weekly Suboxone injection is one of the most common ways patients search for what is, in clinical terms, a weekly buprenorphine extended-release injection. If you have been researching this option, here is what the treatment actually involves, what the evidence says about how well it works, and what to expect if you decide to move forward.
What a Weekly Suboxone Injection Actually Is
Suboxone is a brand name for a sublingual film or tablet that combines buprenorphine and naloxone and dissolves under the tongue. When patients search for a “weekly Suboxone injection,” they are almost always describing a different formulation: an extended-release buprenorphine injection administered by a provider once a week. The most relevant FDA-approved product in this category is Brixadi, which is available in both weekly and monthly dosing schedules.
The active medication is the same in both cases. Buprenorphine is the ingredient doing the therapeutic work. The meaningful difference is how it reaches your system and how often you need to engage with the treatment process.
How It Differs from the Film or Tablet
With the sublingual film or tablet, you dissolve a dose under your tongue every day. That means 365 opportunities each year to miss a dose, run out of medication, or face the daily reminder of being in treatment. The weekly injection replaces all of that with a single provider visit.
Because the medication is released gradually from a subcutaneous depot beneath the skin, steady drug levels replace the daily peaks and valleys you get with oral dosing. There is no medication stored in your home, no daily decision to make, and no visible reminder sitting in a medicine cabinet. For many patients, that shift alone changes the feel of treatment.
What’s Inside the Injection
Buprenorphine is a partial opioid agonist, which means it activates the same receptors in your brain that opioids target, but only partially. It reduces cravings and withdrawal symptoms without producing the full euphoric effect of heroin, fentanyl, or prescription painkillers. The important safety feature here is what pharmacologists call a ceiling effect: beyond a certain dose, increasing the amount does not increase respiratory depression. That is the mechanism that makes opioid overdose lethal, and buprenorphine’s partial agonist profile limits that risk in a way that full agonist opioids do not.
What this means in practice: you get effective craving and withdrawal relief without the life-threatening overdose risk associated with street opioids.
Why Patients and Providers Are Moving Toward Injectable Buprenorphine
A 2021 randomized controlled trial published in The Lancet compared extended-release injectable buprenorphine to daily sublingual buprenorphine in 428 participants over 24 weeks. The injectable group showed significantly higher rates of treatment retention and lower rates of illicit opioid use confirmed by urine drug screening. The mechanism behind those numbers is straightforward: when medication adherence is built into a weekly provider visit rather than relying on daily patient action, fewer people fall through the gaps.
The practical takeaway is that injectable buprenorphine removes many of the friction points that cause sublingual treatment to break down. No daily doses means no diversion risk, which matters for insurance coverage and for patients who have family members at home. It also removes the social stigma some patients experience from filling a daily prescription at a pharmacy. For patients learning how weekly extended-release dosing works, this shift in delivery model is often the deciding factor in whether treatment fits into their actual life.
How the Weekly Injection Works in Practice
The injection is subcutaneous, meaning it goes just beneath the skin, not into a vein. A provider administers it in a clinical setting, typically in the abdomen or upper arm. The appointment itself is short once you are established in treatment, usually 15 to 30 minutes including any brief clinical check-in. You will not inject anything yourself, and there is no medication to take home.
Most patients describe the injection as similar to a standard flu shot: a brief pinch, mild pressure, and then it is done. Mild soreness or firmness at the injection site in the days following is normal and resolves on its own. The medication releases steadily from the deposit under the skin over the course of the week, keeping blood levels stable without requiring any further action on your part.
Starting the Injection: The Induction Step
Before receiving your first weekly injection, you will spend a short period on sublingual buprenorphine. This induction phase exists because starting with an injection before buprenorphine is established in your system can trigger precipitated withdrawal, a rapid and uncomfortable onset of withdrawal symptoms. SAMHSA’s clinical guidance for buprenorphine induction recommends that patients be in mild to moderate withdrawal before the first sublingual dose, and that providers confirm adequate stabilization before transitioning to the injectable form.
The transition timeline is typically a few days to a couple of weeks on the sublingual formulation, though this varies based on your prior opioid use and how quickly you stabilize. Mild withdrawal symptoms during induction, such as restlessness, muscle aches, or disrupted sleep, are expected and temporary. Your provider will monitor your progress and determine when you are ready to move to the injection.
Dosing Flexibility: Weekly vs. Monthly Options
Brixadi is one of two FDA-approved extended-release buprenorphine injectable products. It offers both weekly and monthly dosing schedules, which gives providers and patients more flexibility than the once-monthly Sublocade formulation. The right schedule depends on where you are in treatment, your personal preference, and what your insurance covers.
Early in treatment, a weekly schedule lets your provider check in more frequently and adjust as needed. As you stabilize, some patients transition to the monthly option, which further reduces the number of clinic visits required. That decision is made collaboratively based on how you are doing, not on a fixed protocol. What a full Brixadi treatment program includes typically covers this kind of individualized dosing discussion as part of the initial planning process.
Effectiveness: What the Research Actually Shows
A 2018 randomized Phase 3 trial published in JAMA Internal Medicine followed 428 adults with opioid use disorder over 24 weeks. Participants receiving subcutaneous buprenorphine injections had a treatment success rate of 41.3% compared to 5.0% in the placebo group, measured by weeks with no illicit opioid use confirmed by urine testing. That is a substantial difference, and it is notable that the study population included people who had previously struggled with adherence to daily oral medications.
What this means if you are weighing your options: injectable buprenorphine does not require you to be disciplined about daily dosing to get a consistent therapeutic effect. The medication works continuously between appointments. Week to week, that translates to fewer days spent managing cravings, fewer decisions about whether to take medication, and a treatment rhythm that is built around your provider visit rather than your medicine cabinet.
How It Compares to Daily Sublingual Buprenorphine
A 2022 systematic review in Drug and Alcohol Dependence analyzed 11 studies comparing extended-release injectable buprenorphine to daily sublingual formulations. Across studies, injectable buprenorphine consistently matched or outperformed sublingual on retention rates and illicit opioid use outcomes. Patient-reported satisfaction was also higher in injectable groups, largely driven by the reduction in daily dosing burden.
That said, the injectable format is not automatically the better choice for every patient. Sublingual buprenorphine works well for people who prefer to manage their own medication, who have stable access to a pharmacy, and who do not have concerns about storing medication at home. The injectable format tends to be a stronger fit when daily adherence is a challenge, when removing medication from the home matters for safety or privacy reasons, or when consistent therapeutic levels are particularly important for stability. Bring this comparison directly to your provider, who can weigh your specific situation rather than apply a general rule.
Side Effects to Know Before Your First Injection
A Phase 3 clinical trial of Brixadi published in The Lancet reported that more than 90% of participants tolerated the injection without serious adverse events. The most common side effects were injection site reactions: localized redness, mild swelling, itching, or a small lump under the skin at the injection site. These reactions are typically mild, peak in the first few days after injection, and resolve without treatment.
Beyond the injection site, the side effects you are most likely to notice are consistent with buprenorphine in any form: constipation, nausea, headache, and drowsiness, particularly in the early weeks of treatment. Constipation is the one side effect that tends to persist and is worth managing proactively with dietary fiber and hydration rather than waiting to see if it resolves on its own. Nausea usually lessens after the first few weeks as your body adjusts.
Serious Side Effects and When to Seek Care
Respiratory depression is the most important serious risk to understand. Buprenorphine’s ceiling effect makes this uncommon when taken as prescribed, but the risk increases significantly when buprenorphine is combined with benzodiazepines, alcohol, or other central nervous system depressants. If your breathing feels unusually slow or shallow, you feel unable to stay awake, or someone around you cannot rouse you, that is an emergency.
Other serious but less common concerns include allergic reactions (hives, difficulty breathing, swelling of the face or throat) and liver enzyme changes, which is why providers periodically check liver function. The liver concern is particularly relevant if you have a history of hepatitis. Know these warning signs before you leave your first appointment, and make sure someone in your household knows them too. Having a plan is not an overreaction; it is standard preparation.
Insurance Coverage and Cost in Maryland
Maryland Medicaid covers FDA-approved extended-release buprenorphine injections for opioid use disorder. The relevant managed care program is Maryland HealthChoice, which administers Medicaid benefits for most enrollees across the state. Under HealthChoice, coverage for Brixadi is available when the prescription is associated with an opioid use disorder diagnosis and administered by a qualified provider. Prior authorization may be required depending on your plan, which is why finding a Brixadi provider in Maryland who handles insurance coordination in-office makes a meaningful difference in how smoothly the first appointment goes.
For patients on commercial insurance, coverage varies by plan, but most major insurers cover FDA-approved MAT medications under the mental health and substance use disorder parity rules. For patients without coverage, the Brixadi manufacturer (Braeburn) offers a patient assistance program. According to SAMHSA’s treatment locator guidelines, cost should never be a barrier to an initial conversation with a provider, and most clinics can help identify coverage options before you commit to anything.
The one concrete action to take before your first appointment: call the clinic and ask specifically about prior authorization for Brixadi under your insurance. Getting this confirmed in advance prevents delays on the day of your visit.
What to Expect at Your First Appointment
The first appointment is longer than follow-up visits. Plan for 60 to 90 minutes to cover intake paperwork, a clinical assessment of your substance use history and current health, a conversation about your treatment goals, and the injection itself. Providers offering Brixadi in Maryland typically handle prior authorization and insurance verification as part of the intake process, so bring your insurance card, a photo ID, and a list of any current medications.
The injection itself takes under five minutes. After the injection, most clinics ask you to stay for a brief monitoring period, typically 15 to 30 minutes, to confirm there is no immediate reaction. Then you are done until the following week.
On the question of whether it hurts: it is a subcutaneous injection, comparable to a flu shot or an allergy shot. There is a brief pinch and mild pressure. Some patients notice more sensation than others depending on the injection site and individual sensitivity, but it is not the kind of pain that makes people avoid coming back. The anticipation is usually worse than the experience.
Common Questions About Weekly Buprenorphine Injections
Can You Overdose on the Injection?
Buprenorphine’s ceiling effect means that beyond a certain dose, additional buprenorphine does not produce more respiratory depression. This is the property that distinguishes it from full agonist opioids like heroin or oxycodone. The FDA explicitly cited misuse deterrence as part of the rationale for approving extended-release injectable formulations: because the medication is administered by a provider in a clinical setting and not taken home, there is no opportunity to take more than the prescribed amount. The risk profile is fundamentally different from oral opioids or even sublingual buprenorphine.
That said, the interaction risk with benzodiazepines, alcohol, and other CNS depressants is real and should not be minimized. Overdose in patients on buprenorphine almost always involves a combination of substances, not buprenorphine alone.
What Happens If You Miss an Appointment?
Contact the clinic as soon as possible. Missing a weekly injection appointment does not mean treatment is over. Depending on how much time has passed, your provider will either reschedule the injection within an acceptable window or bridge you with sublingual buprenorphine to maintain therapeutic levels until your next visit. What you should not do is stop treatment abruptly without talking to the clinic first. Withdrawal from buprenorphine after a period of stability is uncomfortable and increases the risk of returning to illicit opioid use. A phone call to the clinic is always the right first move.
Can You Drink Alcohol or Take Other Medications?
Alcohol, benzodiazepines (such as Xanax, Klonopin, or Valium), and other central nervous system depressants significantly increase the risk of respiratory depression when combined with buprenorphine. This is not theoretical: a 2020 analysis from the CDC identified benzodiazepine co-ingestion as a factor in a substantial proportion of opioid-involved overdose deaths. The risk does not disappear just because the buprenorphine is extended-release rather than sublingual.
Before starting the injection, disclose every medication, supplement, and substance you use regularly to your provider. This includes sleep aids, anxiety medications, and alcohol. Your provider needs the full picture to assess your risk and make an informed prescribing decision.
Is the Injection Available for Pregnant Patients?
The American College of Obstetricians and Gynecologists (ACOG) recommends buprenorphine-based medication-assisted treatment as first-line care for opioid use disorder during pregnancy. Untreated opioid use disorder carries significant risks for both the birthing parent and the fetus, and ACOG’s guidance is explicit that the benefits of treatment outweigh the risks of the medication itself. Whether extended-release injectable buprenorphine is the appropriate formulation during pregnancy depends on the specific clinical situation and requires input from both an addiction medicine provider and an OB. This conversation should happen early, and it should involve both specialists together.
Starting the Conversation with a Provider
If weekly buprenorphine injections sound like a fit for where you are right now, the lowest-friction next step is a single phone call. You do not need to have everything figured out first. You do not need to have already stopped using. The call is just to ask whether Brixadi is available, whether your insurance covers it, and what the first appointment looks like.
If you are in Maryland and want to understand what getting started with Brixadi treatment near you actually involves before picking up the phone, that context helps make the first conversation more productive. But the call itself, made this week, is the move that gets treatment started.